Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Multinational, Randomized, Controlled, Open Label Study, Performed in Children With Thermal Burns, to Evaluate the Efficacy and Safety of NexoBrid as Compared to Standard of Care (SOC) Treatment

Next Previous
Trial Profile

A Multicenter, Multinational, Randomized, Controlled, Open Label Study, Performed in Children With Thermal Burns, to Evaluate the Efficacy and Safety of NexoBrid as Compared to Standard of Care (SOC) Treatment

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bromelains (Primary) ; Bromelains (Primary)
  • Indications Burns
  • Focus Registrational; Therapeutic Use
  • Acronyms CIDS
  • Sponsors MediWound

Most Recent Events

  • 01 May 2025 Results assessing the safety and efficacy of bromelain-based debridement in children with deep burns as compared to the standard of care (SOC) eschar removal techniques, published in the Burns.
  • 24 Feb 2025 According to a MediWound media release, The publication of this study presents findings that supported the label expansion of NexoBrid for pediatric patients in the E.U. (2023) and U.S. (2024).
  • 24 Feb 2025 According to a MediWound media release, the company announced the publication of its Phase III Children Innovative Debridement Study (CIDS) in Burns, the peer-reviewed Journal of the International Society for Burn Injuries (ISBI).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top